Avidity Biosciences Inc (NASDAQ: RNA) is 4.68% higher on its value in year-to-date trading and has touched a low of $10.27 and a high of $56.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $29.67 in the last trading session, with the day’s gains setting it 0.77%.
Currently trading at $30.44, the stock is 2.41% and -13.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.39 million and changing 2.60% at the moment leaves the stock -19.42% off its SMA200. RNA registered 199.61% gain for a year compared to 6-month loss of -31.93%. The firm has a 50-day simple moving average (SMA 50) of $35.6442 and a 200-day simple moving average (SMA200) of $37.755325.
The stock witnessed a -3.79% gain in the last 1 month and extending the period to 3 months gives it a -32.95%, and is 5.26% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.87% over the week and 5.97% over the month.
Avidity Biosciences Inc (RNA) has around 253 employees, a market worth around $3.63B and $10.12M in sales. Profit margin for the company is -2772.45%. Distance from 52-week low is 196.40% and -45.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-18.61%).
with sales reaching $1.74M over the same period.The EPS is expected to grow by 1.40% this year, but quarterly earnings will post 1.99% year-over-year. Quarterly sales are estimated to shrink -20.53% in year-over-year returns.
Avidity Biosciences Inc (RNA) Top Institutional Holders
334.0 institutions hold shares in Avidity Biosciences Inc (RNA), with institutional investors hold 111.67% of the company’s shares. The shares outstanding are 118.90M, and float is at 108.26M with Short Float at 14.49%. Institutions hold 106.06% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.16 million shares valued at $660.1 million. The investor’s holdings represent 18.5285% of the RNA Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 10.92 million shares valued at $445.94 million to account for 12.5173 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 8.81 million shares representing 10.0982% and valued at over $359.76 million, while BLACKROCK INC. holds 9.8868 of the shares totaling 8.62 million with a market value of $352.23 million.
Avidity Biosciences Inc (RNA) Insider Activity
The most recent transaction is an insider sale by LEVIN ARTHUR A, the company’s Director. SEC filings show that LEVIN ARTHUR A sold 1,872 shares of the company’s common stock on Jan 21 ’25 at a price of $28.60 per share for a total of $53537.0. Following the sale, the insider now owns 12958.0 shares.
Avidity Biosciences Inc disclosed in a document filed with the SEC on Jan 21 ’25 that MacLean Michael F (Chief Financial Officer) sold a total of 3,287 shares of the company’s common stock. The trade occurred on Jan 21 ’25 and was made at $28.59 per share for $93985.0. Following the transaction, the insider now directly holds 0.1 million shares of the RNA stock.
Still, SEC filings show that on Jan 21 ’25, McCarthy Teresa (Chief Human Resources Officer) disposed off 2,959 shares at an average price of $28.59 for $84612.0. The insider now directly holds 104,908 shares of Avidity Biosciences Inc (RNA).
